Medexus Pharmaceuticals (MDP) Scheduled to Post Quarterly Earnings on Thursday

Medexus Pharmaceuticals (TSE:MDP) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of C$0.03 per share for the quarter.

Medexus Pharmaceuticals (TSE:MDP) last posted its quarterly earnings results on Wednesday, August 7th. The company reported C$0.11 earnings per share for the quarter, topping analysts’ consensus estimates of C$0.04 by C$0.07. The company had revenue of C$37.33 million during the quarter, compared to the consensus estimate of C$36.95 million. Medexus Pharmaceuticals had a return on equity of 3.95% and a net margin of 1.00%.

Medexus Pharmaceuticals Price Performance

Shares of Medexus Pharmaceuticals stock opened at C$2.29 on Wednesday. The stock has a 50-day simple moving average of C$2.56 and a 200-day simple moving average of C$2.17. Medexus Pharmaceuticals has a 52-week low of C$1.44 and a 52-week high of C$3.16. The firm has a market cap of C$56.17 million, a price-to-earnings ratio of 45.80 and a beta of 1.96.

Analyst Ratings Changes

Several analysts have commented on the stock. Stifel Canada raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Stifel Nicolaus upped their price objective on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Finally, Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.